お知らせ • Dec 04
Pharmagreen Biotech Inc. Files Form 15 Pharmagreen Biotech Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common under the Securities Exchange Act of 1934, as amended. お知らせ • May 13
Pharmagreen Biotech Inc. announced delayed 10-Q filing On 05/12/2023, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Feb 09
Pharmagreen Biotech, Inc. Launches Online Sales for Its MaxGenomic(TM) Supplement Product Pharmagreen Biotech Inc., announced that it has completed development of its first formulated nutraceutical product and has commenced online sales via the Shopify ecommerce platform of its MaxGenomic™ Supplement. The company is also pleased to have entered the nutraceutical industry with this product development and be part of this multi-hundred-billion-dollar industry that is growing at a record pace. MaxGenomic™ Supplement comes in a bottle with 60 Enteric capsules (delayed release), for a one- or two-month supply, depending on suggested use. This all-natural product utilizes a combination of fifteen ingredients from medicinal plants and medicinal mushrooms. Pharmagreen’s proprietary blend is unique to the market, by combining mushrooms and herbs in one, delayed release, capsule. A nutrigenomic supplement for the utmost mind and body experience. Nutrigenomics, or nutritional genomics, concerns the relationship between nutrients, diet, and genetic expression. The Company’s new product was formulated to help and assist with repairing damage done to your DNA. This damage happens during cell division and as a result of oxidative stresses due to environmental influences such as pollution. The human body has the ability to repair DNA with special proteins but over time these proteins get used up. By using fungi and plants that contain ß-glucans, polyinosinic-polycytidylic acid, lipopolysaccharides, and many more beneficial compounds it is possible to reverse damage done to your genes. Pharmagreen created this new line of genomic supplements because health and wellness start on the cellular level. Pharmagreen’s team focus is to help and aid, in the sales of MaxGenomic™ Supplement and additional nutraceutical products development. The company has plans to keep adding to the list of honorary sports ambassadors’ representatives. Pharmagreen’s near future plans also include launching additional products of its MaxGenomic™ brand designed for the extremely active, sports professionals and on the go individuals who are looking for immediate help and support before they begin and during their routine. お知らせ • Dec 29
Pharmagreen Biotech Inc. announced delayed annual 10-K filing On 12/28/2022, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. お知らせ • Sep 09
Pharmagreen Biotech Inc. Develops a Proprietary Nutraceutical Formulation and Prepares for Product Launch Pharmagreen Biotech Inc. announced that it has developed its first formulated nutraceutical product and is in the process of organizing the retail sales distribution channels for its new product. The Pharmagreen team is very excited to be launching this nutraceutical product utilizing a combination of fifteen ingredients from medicinal plants and mushrooms. Pharmagreen’s proprietary blend is unique to the market, a nutrigenomic supplement for the utmost mind and body experience. Nutrigenomics, or nutritional genomics, concerns the relationship between nutrients, diet, and genetic expression. The Company’s new product was formulated to repair damage done to your DNA. This damage happens during cell division and as a result of oxidative stresses due to environmental influences such as pollution. The human body has the ability to repair DNA with special proteins but over time these proteins get used up. By using fungi and plants that contain ß-glucans, polyinosinic-polycytidylic acid, lipopolysaccharides, and many more beneficial compounds it is possible to reverse damage done to your genes. Pharmagreen created this new line of genomic supplements because health and wellness start on the cellular level. This product, and new products as they become available, can be purchased through the Company's soon to be launched online store, Shopify, Amazon and other third-party online outlets. Utilizing the Company's expertise in plant genetics and proprietary tissue culture technologies, Pharmagreen's transgenic program uses the newest technology available to research and create nutraceuticals, protein-based formulations, and daily supplements with the potential to improve lives and address a wide variety of disease conditions. お知らせ • Aug 13
Pharmagreen Biotech Inc. announced delayed 10-Q filing On 08/12/2022, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Feb 15
Pharmagreen Biotech Inc. announced delayed 10-Q filing On 02/14/2022, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Aug 17
Pharmagreen Biotech Inc. announced delayed 10-Q filing On 08/16/2021, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • May 15
Pharmagreen Biotech Inc. announced delayed 10-Q filing On 05/14/2021, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Feb 18
Pharmagreen Biotech Inc. Signs LOI to Supply Crude CBD Oil Extracted from Certified Organically Grown Hemp Biomass Pharmagreen Biotech Inc. announced that it has signed a Letter of Intent to supply hemp derived CBD oils extracted from organically grown hemp biomass with Advanced Bio-oil Technologies Ltd. PHBI and ABOT have commenced discussions under the Letter of Intent to begin the business development and to complete a definite on or before April 15, 2021 in the following areas: Pharmagreen will supply the raw CBD hemp oils for ABOT’s product development. Pharmagreen is moving ahead with its plans to set up an extraction facility in Nevada, U.S. and utilize its working relationship with its network of farmer(s) for the production of higher quality hemp oils from certified organically grown hemp biomass; ABOT has a qualified reg A offering from the SEC and to use this offering to raise up to $3 Million for the two projects. ABOT intends to use $1.5 Million for the construction of a certified formulation and product development where the product is being harvested or nearby and invest up to $1.5 Million for Pharmagreen to do the processing of organically grown hemp harvested in Nevada. There is no certainty at this preliminary stage the definite agreement will be concluded; PHBI and ABOT are interested to evolve its mutual relationship into further joint ventures. PHBI has extensive proven knowledge in the production of tissue culture starter plantlets, optimized cultivation techniques for growing large scale CBD hemp biomass as well as ability to produce any plant species plantlets using its proprietary tissue culture technologies. ABOT has developed a network of relationships globally for the manufacturing of products from botanical oils and sees the opportunity in working with PHBI to maximize the production of raw botanical biomass required.
Pharmagreen Biotech Inc. announced that it has signed a Letter of Intent to supply hemp derived CBD oils extracted from organically grown hemp biomass with Advanced Bio-oil Technologies Ltd. PHBI and ABOT have commenced discussions under the Letter of Intent to begin the business development and to complete a definite on or before April 15, 2021 in the following areas: Pharmagreen will supply the raw CBD hemp oils for ABOT’s product development. Pharmagreen is moving ahead with its plans to set up an extraction facility in Nevada, U.S. and utilize its working relationship with its network of farmer(s) for the production of highest quality hemp oils from certified organically grown hemp biomass; ABOT has a qualified reg A offering from the SEC and to use this offering to raise up to $3 Million for the two projects. ABOT intends to use $1.5 Million for the construction of a certified formulation and product development where the product is being harvested or nearby and invest up to $1.5 Million for Pharmagreen to do the processing of organically grown hemp harvested in Nevada. There is no certainty at this preliminary stage the definite agreement will be concluded; PHBI and ABOT are interested to evolve its mutual relationship into further joint ventures. PHBI has extensive proven knowledge in the production of tissue culture starter plantlets, optimized cultivation techniques for growing large scale CBD hemp biomass as well as ability to produce any plant species plantlets using its proprietary tissue culture technologies. ABOT has developed a network of relationships globally for the manufacturing of products from botanical oils and sees the opportunity in working with PHBI to maximize the production of raw botanical biomass required. お知らせ • Feb 13
Pharmagreen Biotech Inc. announced delayed 10-Q filing On 02/12/2021, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Dec 30
Pharmagreen Biotech Inc. announced delayed annual 10-K filing On 12/29/2020, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. お知らせ • Aug 13
Pharmagreen Biotech Inc. announced delayed 10-Q filing On 08/12/2020, Pharmagreen Biotech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.